June 17, 1998 Company Press Release SOURCE: Pharmacia & Upjohn Mirapex May Help Reduce Tremor in Parkinson's Patients, Preliminary Data Suggest BRIDGEWATER, N.J., June 17 /PRNewswire/ -- Preliminary data from two clinical studies by Pharmacia & Upjohn and Boehringer Ingelheim Pharmaceuticals, Inc. suggest that Mirapex Tablets (pramipexole dihydrochloride tablets) may reduce tremor in Parkinson's disease patients. The studies were presented at the 8th meeting of the European Neurological Society (ENS) in Nice, France last week. Parkinson's disease involves progressive loss of brain nerve cells producing dopamine, a neurochemical that transmits nerve signals necessary for normal muscle movements. Symptoms include tremors, rigid muscles, difficulty in initiating movement, a stooped posture, a shuffling gait and slow movement. Tremor is considered one of the most noticeable signs of this disease. Tremor in Parkinson's patients is often called ``rest tremor'' as it occurs at rest and usually abates when the affected limb is in motion. The presence of tremor significantly affects Parkinson's patients' quality of life as it can inhibit basic activities of daily living, such as eating, sleeping and getting dressed. In a double-blind, placebo-controlled trial involving 354 patients with advanced Parkinson's disease, 174 patients treated for 24 months with Mirapex following a 7-week dose escalation period showed 46.8 percent improvement from baseline in tremor at rest as measured by individual items on Part III of the Unified Parkinson's Disease Rating Scale (UPDRS) compared with a reduction of 32.5 percent for 180 patients treated with placebo. The study was presented by Wolfgang H. Oertel, M.D., professor of neurology at Philipps University, Marburg, Germany at the ENS meeting. All 354 patients were receiving concomitant levodopa. In another double-blind, placebo-controlled study by Oertel in 47 patients with advanced Parkinson's disease, a subset of 16 tremor-dominant patients was analyzed. Based on UPDRS Part II/III, there was a reduction of tremor by 60 percent from baseline in 11 patients treated for 12 weeks with Mirapex, while 5 patients in the placebo group showed no improvement from baseline. All 16 patients were receiving concomitant levodopa. ``Preliminary results from these studies warrant further investigation of the long-term impact of Mirapex on the symptomatic reduction of tremor at rest in Parkinson's patients, and a comparison with levodopa or other dopamine agonists, as no controlled study has compared their effects on rest tremor,'' said Oertel. Levodopa, a medication the body converts into dopamine, is commonly used to treat Parkinson's patients. However, levodopa's effectiveness usually diminishes over time and many patients experience recurring symptoms and drug side effects, including spontaneous uncontrolled body movements and sudden temporary loss of mobility. Synthesized by Boehringer Ingelheim and developed jointly with P&U, Mirapex belongs to a class of compounds called dopamine agonists, which stimulates dopamine receptors in the brain. Mirapex was approved by the U.S. Food and Drug Administration (FDA) in July 1997, and in Canada in February 1998, for the treatment of the signs and symptoms of idiopathic Parkinson's disease in early-stage patients without levodopa and in advanced-stage patients with levodopa. The most common side effects of Mirapex reported in clinical trials for early-stage Parkinson's disease were nausea, dizziness, drowsiness and insomnia. The most common side effects of Mirapex taken with levodopa observed in clinical trials for advanced-stage Parkinson's disease were postural hypotension (low blood pressure caused by a change in posture), dyskinesias (impaired movement), extrapyramidal syndrome (involuntary movements), insomnia, dizziness and hallucinations. All patients should be informed that postural hypotension may occur more frequently during initial treatment, and hallucinations can occur at any time during the course of treatment. -- Judith Richards, London, Ontario, Canada [log in to unmask]